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after infliximab treatment; 2) the short-term outcome of a new series of
severe UC patients treated with a three-infusion regimen of infliximab.
Material and methods: Patients from the Italian multicentric study
were evaluated for survival free from colectomy by serial clinical
evaluation. The new series of patients was evaluated for colectomy rate
at 2 months after the first infliximab infusion.
Results: 70 patients who avoid colectomy at 2 months were followed-up
for a median time of 38.8 months (IQR 4–91); among them, 63 patients
(90%) had a follow-up longer than 1 year. During the follow-up period,
15 patients (21%) underwent colectomy. Including early colectomies
reported in the Italian multicentric study (12 of 83 patients, 14.5%), the
overall survival free from colectomy was 66% after a median time of 41
months. A new series of 37 patients underwent treatment with a three-
infusion regimen of infliximab 5 mg/kg for severe steroid-refractory
UC. Seven patients (19%) underwent colectomy at 2 months.
Conclusions: This study confirms that infliximab is an effective rescue
therapy in patients with severe UC unresponsive to intravenous steroid
treatment, with two third of patients surviving free from colectomy after
more than three years from the first infusion.
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Background and aim: Thiopurines are widely used in inflammatory
bowel disease (IBD). It has been reported that co-administration of
aminosalicylates (mesalamine -5ASA- or sulphasalazine –SASP-) sig-
nificantly inhibits TPMT activity, and may result in higher rates of
thiopurine toxicity. Aim of this study was to analyse the effect of 5ASA
or of oral steroids on TPMT activity.
Material and methods: Within a study protocol approved by local Eth-
ical Committee, all consecutive patients (n=169) attending IBD outpa-
tients were recruited. A blood sample was drawn, and intra-erythrocyte
TMPT activity was analysed by means of a standardised high pres-
sure liquid chromatography (HPLC) assays. In patients undergoing
thiopurine treatment, we also evaluated the levels of 6-thioguanosine-
nucleotides (6TGN) and 6-methyl-mercaptopurine (6MMP).
Results: Up to now 169 IBD patients were enrolled (79 Crohn’s disease,
86 ulcerative colitis, 4 indeterminate colitis). Concomitant medications
were: 5ASA in 118 (70%), systemic steroids (GCS) in 16 (10%),
azathioprine (AZA) in 64 (38%) cases, respectively. No difference in
TPMT activity was observed according to gender, age, diagnosis, use of
thiopurines or other clinical variables was noted. Median TPMT activity
was 26.84 (95%CI 24.40-28.63) and 30.32 (825.13-39.8) nmol/h/g Hgb
in patients on 5ASA (5ASA+, n=118) and not on 5ASA (5ASA-, n=51),
respectively (p=0.124).
Data regarding median TPMT activity, and metabolites levels according
to AZA status are reported in Table 1; p values are non-significant for
all comparisons.
Table 1
AZA+ AZA- AZA+ & AZA+ &
5ASA+ 5ASA-
n=64 n=105 n=38 n=26
TPMT nmol/h/g Hgb 27.56 26.98 26.94 34.03
95% CI 25.1- 37.86 23.85-30.85 23.01-32.86 22.52-54.85
6TGN pmol/8×108 RBC 149.98 NA 157.32 163.17
95% CI 121.4-191.9 NA 106.6-213.2 111-212.8
6MMP pmol/8×108 RBC 565.52 NA 615.01 599.61
95% CI 361.5-1,009.3 NA 159.1-1,654.6 239.1-1,351.1
95% CI: 95% confidence interval; n: number; NA: not applicable; Hgb: haemo-
globin; RBC: red blood cell.
Conclusions: Aminosalicylates were prescribed in a large proportion of
IBD patients considered in the study. No significant effects of 5ASA on
TPMT activity were noted, although a non-significant trend towards a
lower TPMT was observed. However this mild effect does not interfere
with metabolites levels. Observation on a larger group of patients in
ongoing in order to confirm these observations. If these data will be
confirmed co-administration of aminosalicylates and thiopurines may
be considered safe.
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